# US Genetic Testing Market

> US Genetic Testing Market Research Report: Size, Share, Trend Analysis By Types (Molecular Genetic Tests/ DNA Tests, Chromosomal Genetic Tests, Biochemical Genetic Tests, Others), By Types (Prescribed Genetic Testing, Direct-to-Consumer Genetic Testing), and By Applications (Reproductive Health, Cancer Screening Ancestry, Predictive and Pre-Symptomatic Testing, Others) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 18.44%
- **2024:** $ 3,700 Million
- **2025:** $ 4,382.28 Million
- **2035:** $ 23,800 Million
- **Key Players:** Illumina (US), Thermo Fisher Scientific (US), Roche (CH), Myriad Genetics (US), 23andMe (US), Genomic Health (US), Invitae (US), Fulgent Genetics (US), Color Genomics (US)

**Report ID:** MRFR/MED/43598-HCR · **Pages:** 200 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-genetic-testing-market-45278

---

## Market Summary

## **US Genetic Testing Market Overview**

As per MRFR analysis, the U.S. Genetic Testing Market Size was estimated at 2.74 (USD Billion) in 2023.The U.S. Genetic Testing Market Industry is expected to grow from 3.68(USD Billion) in 2024 to 16.25 (USD Billion) by 2035. The U.S. Genetic Testing Market CAGR (growth rate) is expected to be around 14.456% during the forecast period (2025 - 2035)

**Key US Genetic Testing Market Trends Highlighted**

The U.S. Genetic Testing Market is experiencing several significant trends driven by various factors. One of the key market drivers is the increasing awareness of personalized medicine, which focuses on tailoring healthcare based on genetic profiles. As healthcare providers and patients recognize the potential benefits of genetic testing in identifying predispositions to certain diseases and personalizing treatment plans, demand has surged. The integration of genetic testing into routine healthcare practices is being encouraged by healthcare policies aimed at improving patient outcomes and reducing healthcare costs.

There are ample opportunities to be explored in the U.S. market, particularly in the areas of direct-to-consumer testing and telemedicine. As consumers seek more control over their health, companies offering genetic testing directly to the public are gaining popularity. The rise of telehealth services has also facilitated wider access to genetic counseling and testing, especially in rural areas where traditional healthcare access may be limited. Such innovations can aid in reaching underserved populations, thereby expanding the consumer base. Recent trends indicate a growing focus on multifactorial conditions and lifestyle diseases rather than just hereditary disorders.

With an increased emphasis on preventative care, genetic testing is becoming pivotal in managing chronic illnesses. Additionally, advancements in technology are enabling quicker, more accurate testing methods, leading to increased adoption by both healthcare providers and consumers. Moreover, regulatory frameworks in the U.S. are evolving to keep pace with these advancements, ensuring that genetic testing remains safe and effective for the population. The intersection of technology and personalized healthcare is indeed shaping the future of the genetic testing market within the United States.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**US Genetic Testing Market Drivers**

**Increasing Prevalence of Genetic Disorders**

The rising occurrence of genetic disorders in the United States is a significant driver propelling the growth of the U.S. Genetic Testing Market Industry. According to the Centers for Disease Control and Prevention (CDC), approximately 1 in 33 babies are born with a genetic disorder in the U.S. This equates to roughly 120,000 infants annually. As awareness increases regarding the importance of identifying genetic risk factors early on, more patients are seeking genetic testing services. Leading organizations such as the American College of Medical Genetics and Genomics have emphasized the importance of genetic testing in diagnosing and managing genetic conditions.

These trends are expected to be supportive of market expansion, as healthcare providers increasingly recommend testing as part of routine healthcare for expectant parents and patients with hereditary disease risk.

**Advancements in Genetic Testing Technologies**

Technological advancements in genetic testing methods are fostering growth within the U.S. Genetic Testing Market Industry. Innovations like next-generation sequencing (NGS) have dramatically reduced the cost and turnaround time for genetic tests. The U.S. Food and Drug Administration (FDA) has also approved numerous NGS-based tests, which further validate and support the credibility of these diagnostics. The improvement in accuracy and reduction in costs make genetic testing more accessible to consumers, resulting in increased adoption.

Companies like Illumina and Thermo Fisher Scientific have played a crucial role in advancing these technologies in the U.S., which contributes to a market poised for rapid expansion.

**Growing Awareness and Acceptance of Personalized Medicine**

The societal shift towards personalized medicine is another key driver of the U.S. Genetic Testing Market Industry. The National Institutes of Health (NIH) reports a rise in the focus on precision health, where treatments and preventive measures are tailored to individuals based on their genetic makeup. This movement is supported by various healthcare bodies, which advocate for the incorporation of genetic testing into standard care practices. As healthcare professionals increasingly recognize the merits of tailored treatments that can improve patient outcomes, the demand for genetic testing is expected to grow significantly.

The integration of genetics into oncology and chronic disease management is further propelled by organizations like the American Society of Clinical Oncology, which highlights the need for genetic insights in treatment planning.

**US Genetic Testing Market Segment Insights**

**Genetic Testing Market Type Insights**

The U.S. Genetic Testing Market reflects a robust segmentation by 'Type,' showcasing an array of testing methodologies essential for advancing personalized medicine and improving patient outcomes. Among these, Molecular Genetic Tests, often referred to as DNA Tests, play a pivotal role in diagnosing genetic conditions and guiding treatment plans, underscoring their significance in the overall landscape of genetic testing. This category is gaining traction due to advancements in sequencing technologies and the growing awareness of genetic predispositions to various diseases, which is increasingly relevant in the U.S. healthcare framework.

Chromosomal Genetic Tests encompass a broad array of tests targeted at identifying chromosomal abnormalities, and they serve as a crucial tool for prenatal diagnosis and cancer genomics, emphasizing the importance of early detection in enhancing treatment effectiveness and patient survival rates.

Biochemical Genetic Tests contribute uniquely by assessing the functional aspects of proteins in an individual's metabolism, making them indispensable in diagnosing metabolic disorders that manifest in childhood, thereby aligning with the U.S. priorities in neonatal screening and public health interventions. The "Others" category encompasses various innovative tests that cater to niche applications, offering solutions that may not fit into the conventional categories and reflecting the ongoing evolution and customization of genetic testing capabilities.

The recognition of genetic testing as a vital part of the modern healthcare ecosystem is evident as more healthcare providers integrate these tests into routine practice. Demand for personalized medicine continues to shape market growth, with an emphasis on tailored treatments based on genetic insights. The increasing prevalence of genetic disorders, combined with the growth in consumer interest inproactive health management, drives innovation and adoption across all types of genetic tests. However, the market faces challenges, including ethical considerations around genetic privacy, the need for regulatory clarity, and the complexities of genetic data interpretation.

Despite these challenges, opportunities abound, particularly as technological advancements improve test accuracy and reduce costs, making genetic testing more accessible to a broader population. As a result, the U.S. Genetic Testing Market is poised for substantial growth, reflecting the ongoing integration of genetic insights into healthcare and the vital role of the various testing types in this evolution.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Genetic Testing Market Type Insights**

The U.S. Genetic Testing Market is becoming increasingly vital in the healthcare landscape, encompassing various types that cater to different needs. The segment of Prescribed Genetic Testing is particularly significant as it contributes to personalized medicine, allowing healthcare providers to tailor treatments based on an individual’s genetic predisposition to certain conditions. This type of testing aids in early diagnosis and optimal patient management, which is becoming a cornerstone in improving healthcare outcomes across the United States. On the other hand, Direct-to-Consumer Genetic Testing is rapidly gaining popularity, driven by increasing consumer interest in personal health and ancestry insights.

This segment empowers individuals to take proactive steps in understanding their genetic makeup, leading to informed lifestyle choices. Increasing acceptance among consumers and advancements in technology are propelling both types of testing forward, allowing for seamless integration into everyday health management. The diversification within the U.S. Genetic Testing Market underscores the growing demand for these services, revealing an evolving landscape that reflects broader trends in personalized medicine and consumer health engagement.

**Genetic Testing Market Application Insights**

The U.S. Genetic Testing Market is experiencing significant growth, particularly within the Application segment, which is pivotal in both clinical and personal health contexts. Reproductive Health plays a crucial role, significantly impacting family planning and enhancing pregnancy outcomes through early screenings for genetic disorders. Cancer Screening incorporates genetic testing as a vital tool for the early detection and prevention of hereditary cancers, allowing individuals to make informed healthcare decisions. Ancestry testing has gained popularity, with many individuals seeking to understand their genetic heritage and lineage, fostering a broader interest in genetic connections.

Meanwhile, Predictive and Pre-Symptomatic Testing serves as an essential avenue for assessing genetic risks for various conditions, empowering individuals with knowledge about their potential health challenges. This diverse segmentation of the U.S. Genetic Testing Market reflects the varying needs and preferences of the population, emphasizing the importance of personalized healthcare. Each segment not only contributes to the overall market dynamics but also addresses critical health concerns, providing unique opportunities for innovation and advancements in genetic technologies.

With the ongoing demand for personalized medicine, the Application segment is positioned to play a significant role in shaping the future of healthcare in the U.S.

**US Genetic Testing Market Key Players and Competitive Insights**

The U.S. Genetic Testing Market has seen significant growth and development in recent years, propelled by advances in technology, increasing awareness of genetic disorders, and the rising demand for personalized medicine. This market is characterized by a competitive landscape with numerous players vying for market share. Companies in this sector are leveraging innovation in genomic research, enhancing their service offerings, and improving testing accuracy to capture the interest of healthcare providers and consumers alike.

The ongoing evolution of regulations, along with a shift towards preventive healthcare, has opened new avenues for growth while presenting challenges related to data privacy and ethical considerations. As a result, the competitive insights of the U.S. Genetic Testing Market highlight not just the strengths of established companies but also the agility of new entrants, making for a dynamic industry environment. LabCorp holds a prominent position in the U.S. Genetic Testing Market, capitalizing on its vast network of laboratories and established reputation within the healthcare community.

The company’s extensive range of genetic tests, encompassing carrier screening, pharmacogenomics, and oncology-focused assessments, showcases its commitment to personalized medicine and patient care. LabCorp's strengths lie in its comprehensive testing services, efficient turnaround times, and broad accessibility for healthcare providers and patients nationwide. Additionally, the company continuously invests in technological advancements and partnerships that enhance its testing capabilities. This strategic approach has enabled LabCorp to maintain a significant market presence while meeting the growing demand for genetic testing services across various medical fields. Exact Sciences has emerged as a leader in the U.S.

Genetic Testing Market, particularly with its focus on early cancer detection, specifically colorectal cancer screening. The company's flagship product, a non-invasive stool DNA test, has garnered attention for its accuracy and convenience. Exact Sciences emphasizes innovation through research and development, which positions the company favorably amid competitive pressures. Its strategic mergers and acquisitions have expanded its capabilities, enabling the integration of advanced technologies and diagnostic expertise. Through collaborations with healthcare providers and ongoing marketing efforts, Exact Sciences actively promotes awareness of its testing services.

The company's strengths include a specialized focus on cancer and genetic screening, robust market positioning, and an unwavering commitment to enhancing patient outcomes, thus solidifying its presence in the evolving landscape of genetic testing in the U.S.

**Key Companies in the US Genetic Testing Market Include**

**US Genetic Testing Market Industry Developments**

The U.S. Genetic Testing Market has experienced significant developments recently, particularly with innovations enhancing precision medicine. In August 2023, LabCorp announced a partnership with Illumina to integrate advanced sequencing technologies, aiming to improve the speed of genetic testing. Additionally, in September 2023, Invitae completed the acquisition of the oncology-focused Strata Oncology, expanding their genomic testing capabilities. Furthermore, Color Genomics recently introduced a new hereditary cancer test that targets high-risk populations, reflecting an increasing trend toward personalized healthcare solutions. Market growth is evident, with companies like Exact Sciences and Myriad Genetics reporting increased revenue attributed to surging demand for genetic insights.

The overall market valuation saw a substantial boost, driven by heightened awareness around genetic testing's role in disease prevention and management. Over the past few years, from 2021 through 2023, there has been a marked increase in regulatory approvals for genetic tests, enhancing market dynamics. The growing emphasis on preventive healthcare in the U.S. further fuels this sector, paving the way for more innovative testing solutions and strategic partnerships among leading firms like Quest Diagnostics and 23andMe.

**Genetic Testing Market Segmentation Insights**

## Market Drivers

### Growing Awareness of Genetic Disorders

There is a growing awareness of genetic disorders among the general population, which is significantly impacting the genetic testing market. Educational initiatives and advocacy groups are playing a vital role in informing individuals about the importance of genetic testing for early detection and management of hereditary conditions. As more people recognize the potential benefits of genetic testing, the demand for these services is likely to increase. For instance, conditions such as cystic fibrosis and sickle cell anemia are being more frequently screened, leading to a projected growth rate of around 11% in the genetic testing market over the next five years. This heightened awareness is expected to drive market expansion as individuals seek proactive healthcare solutions.

### Regulatory Support for Genetic Testing

Regulatory support is emerging as a significant driver for the genetic testing market. The US Food and Drug Administration (FDA) has been actively working to establish clear guidelines for genetic testing products, which is likely to enhance consumer confidence and encourage market growth. By providing a framework for the approval and oversight of genetic tests, regulatory bodies are helping to ensure the safety and efficacy of these products. This regulatory clarity is expected to facilitate innovation and investment in the genetic testing market, as companies can navigate the approval process more effectively. As a result, the market is poised for expansion, with a growing number of tests entering the marketplace.

### Rising Demand for Personalized Medicine

The genetic testing market is experiencing a notable surge in demand for personalized medicine, which tailors medical treatment to individual characteristics. This trend is driven by an increasing awareness among patients and healthcare providers about the benefits of genetic insights in treatment decisions. According to recent data, the market for personalized medicine is projected to reach approximately $2 trillion by 2025, indicating a robust growth trajectory. As patients seek more effective and targeted therapies, Genetic testing plays a crucial role in identifying genetic predispositions and optimizing treatment plans. This shift towards personalized healthcare is likely to enhance patient outcomes and satisfaction, thereby propelling the growth of the genetic testing market.

### Increased Investment in Genomic Research

Investment in genomic research is a key driver of growth in the genetic testing market. Government and private sector funding for research initiatives aimed at understanding genetic diseases and developing new testing methodologies is on the rise. In the US, the National Institutes of Health (NIH) has allocated substantial resources to genomics research, which is likely to foster innovation in genetic testing technologies. This influx of funding not only supports the development of new tests but also enhances the overall understanding of genetic conditions, thereby expanding the market. As research continues to advance, the genetic testing market is expected to benefit from new discoveries and improved testing capabilities.

### Technological Advancements in Genetic Testing

Technological innovations are significantly transforming the genetic testing market, making tests more accessible, accurate, and affordable. Advances in next-generation sequencing (NGS) and bioinformatics have enabled the development of high-throughput testing methods, which can analyze vast amounts of genetic data rapidly. The cost of sequencing a human genome has decreased dramatically, from approximately $100 million in 2001 to around $1,000 today. This reduction in cost, coupled with improved accuracy, is likely to drive increased adoption of genetic testing services among healthcare providers and consumers alike. As technology continues to evolve, the genetic testing market is expected to expand, offering new opportunities for diagnostics and personalized treatment.

## Future Outlook

The [Genetic Testing Market](https://www.marketresearchfuture.com/reports/genetic-testing-market-2009) is projected to grow at an 18.44% CAGR from 2025 to 2035, driven by technological advancements, increased consumer awareness, and regulatory support.

**New opportunities:**

- Development of personalized medicine platforms integrating genetic data
- 
- Expansion of direct-to-consumer genetic testing services
- Investment in AI-driven analytics for predictive genetic insights

By 2035, the market is expected to be robust, driven by innovation and consumer demand.

## Segment Insights

### By Application: Prenatal Testing (Largest) vs. Newborn Screening (Fastest-Growing)

In the US genetic testing market, Prenatal Testing holds the largest share among the application segments, reflecting its critical role in maternal health and risk assessment during pregnancy. Newborn Screening, while smaller in market share, is rapidly gaining traction due to increased awareness and the integration of more comprehensive testing panels in healthcare routines.

Growth trends indicate that Prenatal Testing is driven by advancements in non-invasive testing technologies and growing public awareness of genetic conditions. In contrast, Newborn Screening is expanding swiftly as states update mandates and technology improves, enabling healthcare providers to detect a wider range of conditions at birth, ensuring early intervention and better health outcomes for infants.

Prenatal Testing (Dominant) vs. Carrier Testing (Emerging)

Prenatal Testing is the dominant segment in the application category, characterized by a well-established market foundation, high demand for NIPT (non-invasive prenatal testing), and ongoing research into expanding genetic markers. This segment appeals significantly to expectant parents and healthcare professionals aiming for risk assessment and informed decision-making. Emerging as a noteworthy counterpart, Carrier Testing is witnessing substantial growth due to heightened awareness around genetic disorders and the increasing importance of family planning. As society becomes more conscious of hereditary conditions, Carrier Testing stands out, aligning with changing attitudes towards genetic health and preventative measures.

### By Type: Whole Exome Sequencing (Largest) vs. Non-Invasive Prenatal Testing (Fastest-Growing)

In the US genetic testing market, the distribution of market share among segment values reveals that Whole Exome Sequencing holds the largest share, demonstrating its significance for comprehensive genetic analysis. Following closely are Panel Tests and Whole Genome Sequencing, which collectively play crucial roles in diagnostics. Meanwhile, Single Gene Tests and Non-Invasive Prenatal Testing are also vital, catering to specific testing needs, but command a smaller share in comparison.

Growth trends indicate a rising demand for Non-Invasive Prenatal Testing, driven by increasing awareness and preference for safer testing options. Additionally, advances in genomic technologies are accelerating the adoption of Whole Exome Sequencing, as healthcare providers recognize its value in identifying mutations linked to various diseases. Overall, the segment is characterized by rapid innovation and a focus on personalized medicine, contributing to evolving consumer preferences.

Whole Exome Sequencing (Dominant) vs. Non-Invasive Prenatal Testing (Emerging)

Whole Exome Sequencing stands out as a dominant player in the genetic testing landscape, providing exhaustive insights into protein-coding regions of the genome. It is integral for diagnosing genetic disorders and is extensively utilized in research settings. The rise of precision medicine has further solidified its importance, with clinicians leveraging Whole Exome Sequencing for personalized treatment plans. Conversely, Non-Invasive Prenatal Testing has emerged as a rapidly growing segment, offering mothers-to-be a safer alternative for assessing fetal genetic conditions. This method combines technological advancements with a focus on patient comfort and safety, appealing to expectant parents and healthcare providers alike. Both segments continue to evolve, contributing significantly to the overarching landscape of genetic diagnostics.

### By Service Type: Laboratory Services (Largest) vs. Diagnostic Services (Fastest-Growing)

In the US genetic testing market, Laboratory Services hold the largest market share, providing essential testing capabilities that cater to a wide range of genetic inquiries. This segment benefits from established infrastructure and a strong reputation in accuracy and reliability. On the other hand, Diagnostic Services, while smaller, are rapidly gaining traction and are expected to increase their market presence as awareness of genetic testing grows among healthcare providers and patients alike.

The growth of the Diagnostic Services segment is driven by a rising demand for personalized medicine and preventive care. Technological advancements and strategic collaborations between labs and healthcare institutions are fueling this rapid expansion. As consumers become more informed about genetic conditions, the push for effective diagnostic solutions continues to propel this segment forward, making it a key player in the overall market landscape.

Laboratory Services: Dominant vs. Diagnostic Services: Emerging

Laboratory Services comprise a significant portion of the market, characterized by extensive testing capabilities and state-of-the-art technologies for a wide range of genetic assessments. This segment focuses on delivering accurate results through rigorous protocols, drawing a loyal customer base from healthcare professionals and patients alike. Conversely, Diagnostic Services are emerging with innovative solutions that cater to the evolving needs of genetic testing. This segment is adapting to changes in consumer behavior, emphasizing the importance of timely and precise testing. As a result, Diagnostic Services are positioned to capture a growing share of the market, appealing to a demographic that increasingly values personalized health insights.

### By End User: Clinical Laboratories (Largest) vs. Hospitals (Fastest-Growing)

In the US genetic testing market, clinical laboratories hold the largest market share among end users, thanks to their established infrastructure and comprehensive testing capabilities. Hospitals closely follow as significant contributors, with considerable investments in genetic diagnostics. Research institutions and homecare settings, while growing, represent smaller segments of the market but play vital roles in specialized testing and personalized medicine initiatives.

The growth trends for this segment are largely driven by advancements in genetic technology and increasing awareness of genetic disorders. Hospitals are rapidly expanding their genetic testing services, while clinical laboratories are enhancing their operations to cater to emerging demands. The demand for personalized medicine and preventive healthcare continues to push the adoption of genetic testing in various end-user settings, fostering further growth in the sector.

Clinical Laboratories (Dominant) vs. Hospitals (Emerging)

Clinical laboratories are well-positioned as the dominant players in the US genetic testing market, mainly due to their ability to conduct a high volume of tests with accuracy and efficiency. They possess the necessary certifications and specialized equipment, enabling them to offer a broad range of genetic tests. On the other hand, hospitals are now emerging as increasingly important end users, driven by the growing need to integrate genetic testing into routine clinical practice. They are investing in genetic counseling and testing services, making significant strides in personalization of treatment. As hospitals enhance their capabilities, their role in the genetic testing landscape will likely expand, shaping future market dynamics.

## Competitive Benchmarking

The genetic testing market is currently characterized by a dynamic competitive landscape, driven by advancements in technology, increasing consumer awareness, and a growing emphasis on personalized medicine. Major players such as Illumina (US), Thermo Fisher Scientific (US), and Myriad Genetics (US) are at the forefront, each adopting distinct strategies to enhance their market positioning. Illumina (US) focuses on innovation in sequencing technology, while Thermo Fisher Scientific (US) emphasizes a broad portfolio of genetic testing solutions. Myriad Genetics (US) is increasingly investing in partnerships to expand its testing capabilities, thereby shaping a competitive environment that is both collaborative and competitive.Key business tactics within the market include localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The competitive structure appears moderately fragmented, with several key players exerting influence over various segments. This fragmentation allows for niche players to thrive, while larger companies leverage their resources to dominate the market. The collective influence of these key players fosters a competitive atmosphere that encourages innovation and responsiveness to consumer needs.
In October Illumina (US) announced a strategic partnership with a leading healthcare provider to enhance access to its genomic sequencing services. This collaboration is poised to expand Illumina's reach into underserved markets, potentially increasing its market share and reinforcing its position as a leader in the genetic testing space. The strategic importance of this partnership lies in its ability to facilitate broader adoption of genomic technologies, thereby driving growth in the sector.
In September Myriad Genetics (US) launched a new hereditary cancer test that integrates advanced AI algorithms to improve accuracy and predictive capabilities. This innovation not only enhances the company's product offerings but also positions it as a pioneer in the integration of AI within genetic testing. The strategic significance of this launch is underscored by the growing demand for precision medicine, which is likely to bolster Myriad's competitive edge.
In August Thermo Fisher Scientific (US) completed the acquisition of a smaller genetic testing firm, thereby expanding its capabilities in the oncology testing market. This acquisition is strategically important as it allows Thermo Fisher to diversify its product portfolio and strengthen its position in a rapidly growing segment. The move reflects a broader trend of consolidation within the industry, as companies seek to enhance their competitive advantages through strategic acquisitions.
As of November current trends in the genetic testing market include a pronounced shift towards digitalization, sustainability, and the integration of AI technologies. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise to drive innovation. Looking ahead, competitive differentiation is likely to evolve, with a greater emphasis on technological advancements and supply chain reliability, rather than solely on price. This shift suggests that companies that prioritize innovation and adaptability will be better positioned to thrive in the evolving market.

## Recent News & Developments

The U.S. Genetic Testing Market has experienced significant developments recently, particularly with innovations enhancing precision medicine. In August 2023, LabCorp announced a partnership with Illumina to integrate advanced sequencing technologies, aiming to improve the speed of genetic testing. Additionally, in September 2023, Invitae completed the acquisition of the oncology-focused Strata Oncology, expanding their genomic testing capabilities. Furthermore, Color Genomics recently introduced a new hereditary cancer test that targets high-risk populations, reflecting an increasing trend toward personalized healthcare solutions. Market growth is evident, with companies like Exact Sciences and Myriad Genetics reporting increased revenue attributed to surging demand for genetic insights.

The overall market valuation saw a substantial boost, driven by heightened awareness around genetic testing's role in disease prevention and management. Over the past few years, from 2021 through 2023, there has been a marked increase in regulatory approvals for genetic tests, enhancing market dynamics. The growing emphasis on preventive healthcare in the U.S. further fuels this sector, paving the way for more innovative testing solutions and strategic partnerships among leading firms like Quest Diagnostics and 23andMe.

## Report Scope

| MARKET SIZE 2024 | 3700.0(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 4382.28(USD Million) |
| MARKET SIZE 2035 | 23800.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 18.44% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Illumina (US), Thermo Fisher Scientific (US), Roche (CH), Myriad Genetics (US), 23andMe (US), Genomic Health (US), Invitae (US), Fulgent Genetics (US), Color Genomics (US) |
| Segments Covered | Application, Type, Service Type, End User |
| Key Market Opportunities | Advancements in personalized medicine drive demand for innovative solutions in the genetic testing market. |
| Key Market Dynamics | Technological advancements and regulatory changes drive growth and competition in the genetic testing market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the current valuation of the US genetic testing market?**
A: The market valuation was $3700.0 Million in 2024.

**Q: What is the projected market size for the US genetic testing market by 2035?**
A: The projected valuation for 2035 is $23800.0 Million.

**Q: What is the expected CAGR for the US genetic testing market during 2025 - 2035?**
A: The expected CAGR during this period is 18.44%.

**Q: Which companies are considered key players in the US genetic testing market?**
A: Key players include Illumina, Thermo Fisher Scientific, Roche, Myriad Genetics, 23andMe, Genomic Health, Invitae, Fulgent Genetics, and Color Genomics.

**Q: What segment had the highest valuation in the US genetic testing market in 2024?**
A: Diagnostic Testing had the highest valuation at $1200.0 Million.

**Q: Which type of genetic testing is projected to grow significantly by 2035?**
A: Whole Genome Sequencing is likely to see substantial growth, with a projected valuation of $4760.0 Million.

**Q: What service type generated the most revenue in the US genetic testing market in 2024?**
A: Diagnostic Services generated the most revenue, valued at $1855.0 Million.

**Q: How does the market size for Carrier Testing compare to Newborn Screening in 2024?**
A: Carrier Testing was valued at $700.0 Million, whereas Newborn Screening was valued at $600.0 Million.

**Q: What end user segment is expected to dominate the US genetic testing market by 2035?**
A: Clinical Laboratories are expected to dominate, with a projected valuation of $9500.0 Million.

**Q: What is the valuation of Non-Invasive Prenatal Testing in 2024?**
A: Non-Invasive Prenatal Testing was valued at $185.0 Million in 2024.

**Q: What is the projected market size of the US Genetic Testing Market in 2024?**
A: The US Genetic Testing Market is projected to be valued at 3.5 billion USD in 2024.

**Q: What is the estimated market size of the US Genetic Testing Market by 2035?**
A: By 2035, the US Genetic Testing Market is expected to reach approximately 13.0 billion USD.

**Q: What is the expected CAGR for the US Genetic Testing Market from 2025 to 2035?**
A: The expected compound annual growth rate for the US Genetic Testing Market from 2025 to 2035 is 12.67%.

**Q: Which type of genetic testing is leading the market in terms of valuation in 2024?**
A: Molecular Genetic Tests/DNA Tests are leading the market with a value of 1.5 billion USD in 2024.

**Q: What will be the market value of Chromosomal Genetic Tests in 2035?**
A: By 2035, the market value of Chromosomal Genetic Tests is anticipated to be 3.8 billion USD.

**Q: Who are the major players in the US Genetic Testing Market?**
A: Key players in the US Genetic Testing Market include Illumina, Myriad Genetics, Quest Diagnostics, and 23andMe.

**Q: What is the projected market size for Biochemical Genetic Tests in 2025?**
A: The projected market size for Biochemical Genetic Tests in 2025 is estimated to be around 0.9 billion USD.

**Q: What trends are driving the growth of the US Genetic Testing Market?**
A: Key trends driving growth include advancements in technology, increased awareness, and personalized medicine opportunities.

**Q: What challenges does the US Genetic Testing Market currently face?**
A: The market faces challenges such as regulatory hurdles and ethical concerns regarding genetic information.

**Q: How will the US Genetic Testing Market evolve by 2035?**
A: By 2035, the US Genetic Testing Market is expected to show significant evolution with increased market penetration and technological advancements.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-genetic-testing-market-45278*